Exostoses, Multiple Hereditary
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Circle PharmaCA - South SF
1 programEstablishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BCN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IpsenPalovarotene 2.5 mg
Circle PharmaEstablishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC
Clinical Trials (2)
Total enrollment: 2,193 patients across 2 trials
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
Start: Mar 2018Est. completion: Oct 2020193 patients
Phase 2Terminated
NCT00473850Circle PharmaEstablishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC
Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC
Start: Dec 1998Est. completion: Mar 20232,000 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.